You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

copanlisib

Showing 1 - 25 of 59
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Rituximab
  • Copanlisib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Advanced Urothelial Carcinoma Trial in Boston (copanlisib, Avelumab)

Not yet recruiting
  • Advanced Urothelial Carcinoma
  • Boston, Massachusetts
    VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain,
Jan 13, 2023

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Duarte, California
  • +2 more
Nov 10, 2022

Metastatic Castration-resistant Prostate Cancer Trial in San Francisco, Providence (Rucaparib, Copanlisib)

Active, not recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • San Francisco, California
  • +1 more
Nov 22, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Duarte, California
  • +1 more
Aug 3, 2022

Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)

Terminated
  • Estrogen Receptor Positive
  • +16 more
  • Biopsy of Breast
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022

Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)

Recruiting
  • Endometrial Cancer
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2022

Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)

Recruiting
  • Leukemia, Acute Lymphocytic
  • Copanlisib
  • Durham, North Carolina
    Duke Cancer Center
Jun 28, 2022

Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
May 13, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Biopsy
  • +3 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Aug 5, 2022

HER2 Positive Breast Cancer Trial in Ireland (Copanlisib, Trastuzumab)

Completed
  • HER2 Positive Breast Cancer
  • Cork, Ireland
  • +4 more
Jul 25, 2022

Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

Completed
  • Mature T-Cell and NK-Cell Neoplasm
  • Hwasun-gun, Jeollanam-do, Korea, Republic of
    Chonnam National University Hwasun Hospital
Jun 9, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial

Withdrawn
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • (no location specified)
May 24, 2022

Non Small Cell Lung Cancer Trial in Lexington (Durvalumab, Copanlisib)

Recruiting
  • Non Small Cell Lung Cancer
  • Lexington, Kentucky
    Markey Cancer Center
Feb 21, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +6 more
  • Boston, Massachusetts
  • +5 more
Jan 7, 2023

Non-Hodgkin Lymphoma Trial in Switzerland (Copanlisib, Venetoclax)

Terminated
  • Non-Hodgkin Lymphoma
  • Basel, Switzerland
  • +5 more
Mar 18, 2022

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +7 more
  • Aurora, Colorado
  • +7 more
Nov 29, 2022

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +4 more
  • Birmingham, Alabama
  • +12 more
Nov 9, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Suspended
  • Anatomic Stage III Breast Cancer AJCC v8
  • +12 more
  • Copanlisib Hydrochloride
  • Eribulin Mesylate
  • Gainesville, Florida
  • +10 more
Nov 16, 2022

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022